CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

Completed · Phase 1

Conditions studied: Non-Hodgkin's Lymphoma

In brief

Purpose: This study will evaluate the safety of CHOP plus Alemtuzumab in patients with T/NK cell lymphomas and CD-20 negative large B-cell lymphomas who have not had previous treatments. The biological response of lymphoma cells and the immune system to this drug combination will also be measured in patients before, during, and after therapy administration.

Key facts

Study ID

NCT00323323

Run by

Ohio State University Comprehensive Cancer Center

People needed

24

Starts

2004-03-01

Expected to finish

2016-10-01

Last updated by the study team

2017-01-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• CD-20 Negative
• Previous treatment permitted: radiation, electron beam radiotherapy, PUVA, corticosteroids, IFN, low dose methotrexate, retinoids, Ontak
• CNS disease permitted

You may not qualify if…

• Pregnant or Nursing
• prior Alemtuzumab
• history of active Hep C

Where it is running

• Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.